Skip to content

This is an observational study to determine the efficacy and safety of vitamin-c in facial photodamage

Post marketing surveillance for efficacy and safety evaluation of vitamin-c 15% w/w in facial photodamage

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2010/091/001161
Enrollment
24
Registered
2010-08-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Facial photodamage

Interventions

Intervention1: Vitamin C 15 % w/w: To apply 7 drops on the face once a day in morning Control Intervention1: NIL: NIL

Sponsors

Cipla Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects willing to give written informed consent. 2.Subjects of either sex above 18 years of age. 3.Subjects with diagnosis of early to moderate photodamage 4.In the opinion of the investigator, able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion criteria: 1.Subjects with hypersensitivity to study drug or any of it?s excipients of its formulation. 2.Judged by Investigator to be inappropriate as subjects.

Design outcomes

Primary

MeasureTime frame
Mean change in Global clinical score for photodamageTimepoint: At week 4, 8 and 12 from baseline

Secondary

MeasureTime frame
1.Mean change in Patients self assessmentTimepoint: At week 4, 8 and 12 from baseline;2. Change in photographic assessmentTimepoint: At week 12 from baseline;3. Skin tolerability will be notedTimepoint: At week 12 from baseline;4. Incidence and nature of adverse eventsTimepoint: At week 12 from baseline;5. Incidence of drug related adverse reactionsTimepoint: At week 12 from baseline

Countries

India

Contacts

Public ContactDr Maya Vedamurthy
jgogtay@cipla.com022-23025412

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026